11.80
6.35%
-0.80
Curis Inc stock is currently priced at $11.80, with a 24-hour trading volume of 26,990.
It has seen a -6.35% decreased in the last 24 hours and a -26.02% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $12.86 pivot point. If it approaches the $11.28 support level, significant changes may occur.
Previous Close:
$12.60
Open:
$12.66
24h Volume:
26,990
Market Cap:
$69.55M
Revenue:
$10.02M
Net Income/Loss:
$-47.41M
P/E Ratio:
-1.2647
EPS:
-9.33
Net Cash Flow:
$-38.43M
1W Performance:
-24.94%
1M Performance:
-26.02%
6M Performance:
+60.54%
1Y Performance:
+1,226%
Curis Inc Stock (CRIS) Company Profile
Name
Curis Inc
Sector
Industry
Phone
617 503 6500
Address
Building C, Suite 500 128 Spring Street, Lexington, MA
Curis Inc Stock (CRIS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-04-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
Oct-13-21 | Initiated | Raymond James | Outperform |
Mar-25-21 | Initiated | B. Riley Securities | Buy |
Jul-29-20 | Initiated | Laidlaw | Buy |
Jul-17-20 | Initiated | Cantor Fitzgerald | Overweight |
Oct-24-17 | Initiated | Guggenheim | Buy |
Mar-02-16 | Initiated | Sun Trust Rbsn Humphrey | Buy |
Nov-09-15 | Reiterated | ROTH Capital | Buy |
Aug-11-15 | Initiated | FBR Capital | Outperform |
Jan-22-15 | Reiterated | Oppenheimer | Outperform |
Jan-21-15 | Reiterated | ROTH Capital | Buy |
May-09-14 | Reiterated | Oppenheimer | Outperform |
Oct-02-13 | Initiated | Robert W. Baird | Outperform |
Sep-30-13 | Initiated | Chardan Capital Markets | Buy |
Nov-14-12 | Initiated | Stifel Nicolaus | Hold |
Jan-31-12 | Reiterated | Brean Murray | Buy |
Jan-31-12 | Reiterated | Summer Street Research | Buy |
Dec-09-11 | Initiated | Oppenheimer | Outperform |
Oct-06-11 | Initiated | Summer Street Research | Buy |
Sep-22-11 | Initiated | MLV Capital | Buy |
Mar-21-11 | Reiterated | Brean Murray | Buy |
Feb-26-10 | Reiterated | Roth Capital | Buy |
Jan-07-10 | Initiated | Roth Capital | Buy |
View All
Curis Inc Stock (CRIS) Latest News
Curis' (CRIS) “Overweight” Rating Reaffirmed at Cantor Fitzgerald - Defense World
Defense World
Curis announces data from ongoing TakeAim Leukemia study - TipRanks.com - TipRanks
TipRanks
Curis shares target cut by $9, retains buy rating - Investing.com Canada
Investing.com Canada
Curis' (CRIS) Buy Rating Reiterated at HC Wainwright - MarketBeat
MarketBeat
Curis, Inc. (NASDAQ:CRIS) Short Interest Update - MarketBeat
MarketBeat
(CRIS) Investment Report - Stock Traders Daily
Stock Traders Daily
Curis Inc Stock (CRIS) Financials Data
Curis Inc (CRIS) Revenue 2024
CRIS reported a revenue (TTM) of $10.02 million for the quarter ending December 31, 2023, a -1.37% decline year-over-year.
Curis Inc (CRIS) Net Income 2024
CRIS net income (TTM) was -$47.41 million for the quarter ending December 31, 2023, a +16.34% increase year-over-year.
Curis Inc (CRIS) Cash Flow 2024
CRIS recorded a free cash flow (TTM) of -$38.43 million for the quarter ending December 31, 2023, a +29.80% increase year-over-year.
Curis Inc (CRIS) Earnings per Share 2024
CRIS earnings per share (TTM) was -$8.96 for the quarter ending December 31, 2023, a +26.74% growth year-over-year.
About Curis Inc
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Cap:
|
Volume (24h):